Eficacia del tratamiento antirretroviral de inicio basado en lopinavir/ritonavir más 2 análogos de nucleósidos/nucleótidos en pacientes infectados por el virus de la inmunodeficiencia humana-1
Efficacy of initial antiretroviral therapy based on lopinavir/ritonavir plus 2 nucleoside/nucleotide analogs in patients with human immunodeficiency virus type 1 infection
Laura Zamora, José M. Gatell
Autor para correspondencia
Servicio de Infecciones, Hospital Clínic-IDIBAPS, Universidad de Barcelona, Barcelona, España
Leído
2237
Vecesse ha leído el artículo
1084
Total PDF
1153
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 12 | 10 | 6 | 16 |
| 2025 11 | 32 | 23 | 55 |
| 2025 10 | 16 | 15 | 31 |
| 2025 9 | 9 | 14 | 23 |
| 2025 8 | 11 | 9 | 20 |
| 2025 7 | 19 | 6 | 25 |
| 2025 6 | 11 | 2 | 13 |
| 2025 5 | 19 | 3 | 22 |
| 2025 4 | 8 | 2 | 10 |
| 2025 3 | 10 | 2 | 12 |
| 2025 2 | 5 | 5 | 10 |
| 2025 1 | 5 | 2 | 7 |
| 2024 12 | 7 | 2 | 9 |
| 2024 11 | 7 | 5 | 12 |
| 2024 10 | 8 | 2 | 10 |
| 2024 9 | 11 | 5 | 16 |
| 2024 8 | 16 | 6 | 22 |
| 2024 7 | 9 | 6 | 15 |
| 2024 6 | 11 | 4 | 15 |
| 2024 5 | 9 | 4 | 13 |
| 2024 4 | 7 | 7 | 14 |
| 2024 3 | 6 | 5 | 11 |
| 2024 2 | 8 | 5 | 13 |
| 2024 1 | 6 | 4 | 10 |
| 2023 12 | 9 | 6 | 15 |
| 2023 11 | 11 | 13 | 24 |
| 2023 10 | 12 | 2 | 14 |
| 2023 9 | 9 | 0 | 9 |
| 2023 8 | 5 | 0 | 5 |
| 2023 7 | 4 | 4 | 8 |
| 2023 6 | 5 | 0 | 5 |
| 2023 5 | 8 | 3 | 11 |
| 2023 4 | 4 | 3 | 7 |
| 2023 3 | 5 | 1 | 6 |
| 2023 2 | 9 | 0 | 9 |
| 2022 1 | 11 | 2 | 13 |
| 2022 12 | 11 | 5 | 16 |
| 2022 11 | 16 | 6 | 22 |
| 2022 10 | 10 | 5 | 15 |
| 2022 9 | 10 | 8 | 18 |
| 2022 8 | 15 | 8 | 23 |
| 2022 7 | 9 | 6 | 15 |
| 2022 6 | 14 | 6 | 20 |
| 2022 5 | 18 | 4 | 22 |
| 2022 4 | 8 | 8 | 16 |
| 2022 3 | 24 | 13 | 37 |
| 2022 2 | 17 | 5 | 22 |
| 2021 1 | 6 | 4 | 10 |
| 2021 12 | 10 | 8 | 18 |
| 2021 11 | 8 | 11 | 19 |
| 2021 10 | 7 | 11 | 18 |
| 2021 9 | 6 | 8 | 14 |
| 2021 8 | 6 | 9 | 15 |
| 2021 7 | 7 | 4 | 11 |
| 2021 6 | 7 | 9 | 16 |
| 2021 5 | 11 | 7 | 18 |
| 2021 4 | 22 | 9 | 31 |
| 2021 3 | 12 | 8 | 20 |
| 2021 2 | 4 | 7 | 11 |
| 2020 1 | 6 | 9 | 15 |
| 2020 12 | 14 | 8 | 22 |
| 2020 11 | 13 | 7 | 20 |
| 2020 10 | 6 | 4 | 10 |
| 2020 9 | 11 | 11 | 22 |
| 2020 8 | 10 | 9 | 19 |
| 2020 7 | 15 | 18 | 33 |
| 2020 6 | 8 | 5 | 13 |
| 2020 5 | 15 | 12 | 27 |
| 2020 4 | 3 | 12 | 15 |
| 2020 3 | 13 | 5 | 18 |
| 2020 2 | 9 | 19 | 28 |
| 2020 1 | 3 | 3 | 6 |
| 2019 12 | 9 | 23 | 32 |
| 2019 11 | 11 | 4 | 15 |
| 2019 10 | 5 | 5 | 10 |
| 2019 9 | 13 | 15 | 28 |
| 2019 8 | 11 | 19 | 30 |
| 2019 7 | 12 | 18 | 30 |
| 2019 6 | 10 | 39 | 49 |
| 2019 5 | 23 | 103 | 126 |
| 2019 4 | 1 | 35 | 36 |
| 2019 3 | 3 | 5 | 8 |
| 2019 2 | 6 | 8 | 14 |
| 2019 1 | 1 | 2 | 3 |
| 2018 12 | 2 | 4 | 6 |
| 2018 11 | 3 | 2 | 5 |
| 2018 10 | 4 | 5 | 9 |
| 2018 9 | 1 | 6 | 7 |
| 2018 8 | 0 | 6 | 6 |
| 2018 7 | 0 | 3 | 3 |
| 2018 6 | 1 | 4 | 5 |
| 2018 5 | 1 | 9 | 10 |
| 2018 4 | 0 | 6 | 6 |
| 2018 3 | 2 | 3 | 5 |
| 2018 2 | 0 | 1 | 1 |
| 2018 1 | 2 | 1 | 3 |
| 2017 12 | 0 | 1 | 1 |
| 2017 11 | 3 | 0 | 3 |
| 2017 10 | 4 | 2 | 6 |
| 2017 9 | 2 | 7 | 9 |
| 2017 8 | 1 | 0 | 1 |
| 2017 7 | 6 | 2 | 8 |
| 2017 6 | 5 | 3 | 8 |
| 2017 5 | 6 | 2 | 8 |
| 2017 4 | 7 | 2 | 9 |
| 2017 3 | 15 | 38 | 53 |
| 2017 2 | 8 | 5 | 13 |
| 2016 1 | 3 | 2 | 5 |
| 2016 12 | 12 | 6 | 18 |
| 2016 11 | 15 | 5 | 20 |
| 2016 10 | 21 | 3 | 24 |
| 2016 9 | 21 | 9 | 30 |
| 2016 8 | 21 | 5 | 26 |
| 2016 7 | 10 | 3 | 13 |
| 2016 6 | 9 | 10 | 19 |
| 2016 5 | 9 | 18 | 27 |
| 2016 4 | 6 | 13 | 19 |
| 2016 3 | 7 | 17 | 24 |
| 2016 2 | 7 | 17 | 24 |
| 2015 1 | 5 | 25 | 30 |
| 2015 12 | 8 | 7 | 15 |
| 2015 11 | 9 | 3 | 12 |
| 2015 10 | 9 | 10 | 19 |
| 2015 9 | 6 | 6 | 12 |
| 2015 8 | 5 | 9 | 14 |
| 2015 7 | 13 | 7 | 20 |
| 2015 6 | 11 | 5 | 16 |
| 2015 5 | 5 | 5 | 10 |
| 2015 4 | 6 | 15 | 21 |
| 2015 3 | 7 | 16 | 23 |
| 2015 2 | 11 | 3 | 14 |
| 2015 1 | 3 | 8 | 11 |
Mostrar todo
